Verastem Secures $16 Million in Series A Financing for Novel Cancer Stem Cell Drugs
Verastem Inc. closed a $16 million Series A financing round. Founding investor, Longwood Founders Fund, participated in the round. It was joined by Bessemer Venture Partners, Cardinal Partners and MPM Capital. Verastem of Boston, Mass., is a biopharmaceutical company that developing cancer treatments.
16 November 2010•2 mins read
